In this episode of the Beyond Compliance Podcast, produced with Applied Clinical Trials, Dr. Joseph Geraci joins Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, to discuss how explainable AI, not black-box prediction, can reveal clinically meaningful patient subgroups to provide drug development leaders with actionable precision analytics beyond average patient treatment effects.

This conversation dives into how averaging patients into broad disease categories can obscure real treatment effects and hide the subgroups most likely to respond to a therapy.

Key Takeaways:

• Most drug failures aren’t due to bad science, but to trials that fail to account for biological heterogeneity, leaving real economic and clinical value on the table.
• Grouping patients under broad disease labels and averaging treatment effects can dilute or hide meaningful response signals in specific subgroups.
• Black-box AI models, built on the same averaging techniques that power large language models, are poorly suited to clinical trial data and difficult to defend in regulated drug development because sponsors need to understand and explain how a conclusion was reached.
• Insights from earlier-phase trials can potentially be transported into later, more expensive phases, helping sponsors better target enrollment and interpret placebo response before reaching costly Phase III trials.
• NetraAI is built to recognize when it doesn’t have enough information and can acknowledge when it doesn’t understand a given patient population, rather than forcing a prediction, allowing it to surface model-derived patient subgroups characterized by clinically recognizable characteristics clinicians can act on.

Other ways to listen:

https://www.appliedclinicaltrialsonline.com/view/beyond-compliance-netramark-joseph-geraci-phd-ai-driven-patient-subgroups-explainable